<DOC>
	<DOCNO>NCT00003148</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill acute myelogenous leukemia cell . PURPOSE : Phase II trial study effectiveness interleukin-2 treating patient acute myelogenous leukemia relapse follow previous treatment .</brief_summary>
	<brief_title>Interleukin-2 Treating Patients With Relapsed Refractory Acute Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I. Assess therapeutic activity interleukin-2 ( IL-2 ) patient slowly progress acute myeloid leukemia limit bone marrow blastosis either first relapse autologous bone marrow peripheral blood stem cell transplantation , advanced disease ( i.e. , refractory chemotherapy regimen ) . II . Characterize acute side effect IL-2 patient . OUTLINE : This open label , nonrandomized , multicenter study . Patients stratify two category prior fail treatment ( first relapse autologous bone marrow peripheral blood stem cell transplantation v first subsequent relapse either refractory eligible conventional treatment ) . Interleukin-2 ( IL-2 ) administer continuous intravenous infusion 5 consecutive day daily escalate dos first cycle . When individual maximum tolerate dose ( MTD ) determine , 3 cycle give MTD . There 3 day rest treatment cycle . After induction phase , maintenance cycle IL-2 administer start 4 week last induction treatment . Maintenance cycle IL-2 administer subcutaneously 5 consecutive day every 4 week 2 year , subsequently every month maximum 3 year . Treatment continue disease progression unacceptable toxicity maximum 5 year . Patients follow every 4 week first 2 year , every 8 week next 3 year document progression , every 3 month death . PROJECTED ACCRUAL : A maximum 86 ( 57 transplant ; 29 patient nontransplanted ) patient accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute myeloid leukemia ( AML ) relapse prior treatment ( ) Slowly progress disease define bone marrow blast great 5 % le 30 % confirm least 2 marrow aspirate take 2 week apart Must either : First relapse autologous bone marrow peripheral blood stem cell transplantation OR First subsequent relapse either refractory eligible conventional treatment regimens PATIENT CHARACTERISTICS : Age : 18 60 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Not specify Hepatic : Bilirubin le 2 time normal Renal : Creatinine le 2 time normal Cardiovascular : Ejection fraction normal Pulmonary : PLCO diffusion great 60 % Other : No active uncontrolled infection No progressive malignant disease Not poor medical risk nonmalignant systemic disease PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : No concurrent steroids Radiotherapy : Not specify Surgery : Not specify Other : No concurrent indomethacin No concurrent anticancer investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
</DOC>